Eu­ro­pean Com­mis­sion clears As­traZeneca's $39B bid for Alex­ion and a fu­ture in rare dis­eases. Now there's just a fi­nal hur­dle

As­traZeneca has cleared the penul­ti­mate hur­dle be­fore of­fi­cial­ly com­plet­ing its $39 bil­lion ac­qui­si­tion of Alex­ion.

The Eu­ro­pean Com­mis­sion has giv­en its bless­ing to the pro­posed deal af­ter a re­view, the lat­est green light fol­low­ing clear­ances by the Unit­ed States’ FTC and its coun­ter­parts in 11 coun­tries. The UK’s CMA will be the last one to de­cide — and it has un­til Ju­ly 21.

As­sum­ing an OK, As­traZeneca has pre­vi­ous­ly said it ex­pects to close the deal in Q3.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER